Biotech Insider Selling: Achillion Pharmaceuticals (NASDAQ:ACHN), Questcor Pharmaceuticals(NASDAQ:QCOR), Seattle Genetics (NASDAQ:SGEN), Repligen Corporation (NASDAQ:RGEN), bluebird bio (NASDAQ:BLUE)

Technology Stocks News 15

Achillion Pharmaceuticals Inc (NASDAQ:ACHN) major shareholder Qvt Associates Gp Llc sold 128,649 shares of the company’s stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $7.66, for a total transaction of $985,451.34. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock performance was -6.32% in last session and finished the day at $6.38. Traded volume was 21.04million shares in the last session and the average volume of the stock remained 3.75million shares. The beta of the stock remained 1.89. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) insider ownership is 13.04%.

Questcor Pharmaceuticals Inc (NASDAQ:QCOR) Insider Michael H. Mulroy sold 10,000 shares of the company stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $88.57, for a total value of $885,700.00. Following the completion of the transaction, the insider now directly owns 77,063 shares of the company’s stock, valued at approximately $6,825,470. Questcor Pharmaceuticals Inc (NASDAQ:QCOR) dropped -2.40 percent to $88.81 Thursday on volume of 1.19million shares. The intra-day range of the stock was $88.66 to $90.99. Questcor Pharmaceuticals Inc (NASDAQ:QCOR) has a market capitalization of $5.42billion.

Seattle Genetics Inc (NASDAQ:SGEN) CEO Clay B. Siegall sold 11,200 shares of Seattle Genetics stock on the open market in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $40.14, for a total transaction of $449,568.00. Following the transaction, the chief executive officer now directly owns 525,217 shares of the company’s stock, valued at approximately $21,082,210. Seattle Genetics, Inc. (NASDAQ:SGEN)’s stock on June 12, 2014 reported a decrease of -0.05% to the closing price of $40.10. Its fifty two weeks range is $28.15 -$55.99. The total market capitalization recorded $4.94billion. The overall volume in the last trading session was 741,406.00million shares. In its share capital, SGEN has 123.15million outstanding shares.

Repligen Corp. (NASDAQ:RGEN) SVP Daniel P. Witt sold 47,709 shares of the company’s stock on the open market in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $20.56, for a total transaction of $980,897.04. Following the completion of the sale, the senior vice president now directly owns 10,000 shares of the company’s stock, valued at approximately $205,600. On Thursday, shares of Repligen Corporation (NASDAQ:RGEN) dropped -1.41% to close the day at $19.54. Company return on investment (ROI) is 15.40% and its monthly performance is recorded as 7.66%. Repligen Corporation (NASDAQ:RGEN) quarterly revenue growth is 30.97%.

bluebird bio Inc (NASDAQ:BLUE) COO Jeffrey T. Walsh unloaded 6,000 shares of the stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $24.23, for a total transaction of $145,380.00. bluebird bio Inc (NASDAQ:BLUE) stock performance was 0.44% in last session and finished the day at $25.27. Traded volume was 87,626.00million shares in the last session and the average volume of the stock remained 235.45K shares. bluebird bio Inc (NASDAQ:BLUE) insider ownership is 1.70%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone